Oarsman Capital Inc. Has $2.17 Million Stock Position in Bristol Myers Squibb Company $BMY

Key Points

• Oarsman Capital Inc. has increased its position in Bristol Myers Squibb by 36.3%, owning a total of 35,640 shares valued at approximately $2,174,000 as of the latest SEC filing.
• The company's recent quarterly earnings exceeded estimates, reporting an EPS of $1.46, surpassing the consensus of $1.07, with revenue of $12.27 billion for the quarter.
• Bristol Myers Squibb announced a quarterly dividend of $0.62, translating to an annualized dividend yield of 5.2%, although the dividend payout ratio is currently at 100%.

Oarsman Capital Inc. lifted its stake in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 36.3% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 35,640 shares of the biopharmaceutical company's stock after buying an additional 9,483 shares during the quarter. Oarsman Capital Inc.'s holdings in Bristol Myers Squibb were worth $2,174,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. OMERS ADMINISTRATION Corp grew its holdings in Bristol Myers Squibb by 0.7% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 112,711 shares of the biopharmaceutical company's stock worth $6,874,000 after buying an additional 818 shares in the last quarter. D L Carlson Investment Group Inc. bought a new position in shares of Bristol Myers Squibb in the first quarter valued at $1,510,000. Truvestments Capital LLC increased its holdings in shares of Bristol Myers Squibb by 779.1% in the first quarter. Truvestments Capital LLC now owns 59,796 shares of the biopharmaceutical company's stock valued at $3,647,000 after buying an additional 52,994 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new position in Bristol Myers Squibb during the 1st quarter valued at about $147,000. Finally, B. Metzler seel. Sohn & Co. AG lifted its position in shares of Bristol Myers Squibb by 103.1% in the first quarter. B. Metzler seel. Sohn & Co. AG now owns 160,075 shares of the biopharmaceutical company's stock worth $9,763,000 after purchasing an additional 81,276 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on BMY. Morgan Stanley reaffirmed a "hold" rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Citigroup decreased their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a "neutral" rating for the company in a research note on Friday, August 1st. Daiwa Capital Markets downgraded Bristol Myers Squibb from an "outperform" rating to a "neutral" rating and set a $42.00 price target for the company. in a research note on Tuesday, August 5th. Wall Street Zen downgraded Bristol Myers Squibb from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Finally, Daiwa America downgraded Bristol Myers Squibb from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, fifteen have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $56.38.

Bristol Myers Squibb Trading Down 0.2%

Bristol Myers Squibb stock traded down $0.09 during trading hours on Tuesday, reaching $47.10. 4,274,659 shares of the company's stock traded hands, compared to its average volume of 13,111,253. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. Bristol Myers Squibb Company has a fifty-two week low of $42.96 and a fifty-two week high of $63.33. The firm has a market capitalization of $95.86 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 2.41 and a beta of 0.35. The firm's 50 day moving average is $47.05 and its 200-day moving average is $50.66.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 EPS for the quarter, beating analysts' consensus estimates of $1.07 by $0.39. The company had revenue of $12.27 billion during the quarter, compared to analysts' expectations of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%.Bristol Myers Squibb's revenue was up .6% on a year-over-year basis. During the same period in the prior year, the business posted $2.07 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. On average, analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, August 1st. Investors of record on Thursday, July 3rd were given a $0.62 dividend. The ex-dividend date was Thursday, July 3rd. This represents a $2.48 annualized dividend and a dividend yield of 5.3%. Bristol Myers Squibb's payout ratio is currently 100.00%.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.